Table 1 Patient characteristics at baseline and six months after treatment
Patient NoAge (y) / disease duration (y)Earlier treatment (total CYC (g)); treatment immediately before RTX in bold italicsACR criteria fulfilled at inclusion*Main disease manifestationsBILAG at baseline/after 6 months†SLICC-DI at entryBaseline nephritis WHO classification/proteinuria
133 / 11AML, MTX, AZA, CYC (6.1 g)6,7,10,11NephritisA/C0IIIb/0.2 g
225 / 12AML, AZA, CyA, CYC (9.4 g)1,2,3,5,6,7,10,11NephritisA/B0IVc/1.6 g
327 / 11AML, MMF, CyA, CYC (6.1 g)1,2,3,5,7,9,10,11Nephritis, serositis,A/D B/D3Vb/5.3 g
456 / 20AZA, MTX, CyA, thalidomide, prasterone, IvIg, CYC (3.6 g)1,2,3,5,7,9,10,11Vasculitis‡, cutaneous, destructiveA/C A/C A/C3
526 / 10AML, CYC(7.8 g)1,2,3,7,9,10,11Nephritis, generalA/C A/C0IVb/4.6 g
632 / 7AZA, MTX, CyA, CYC (2.8 g)1,5,7,9,10,11Quinckes oedema, haematologicalA/D B/B0
750 / 4AML, MTX, AZA, CyA, prasterone IvIg, leflunomid, CYC (3.0 g)3,5,6,10,11Arthritis, serositisA/C B/D0
819 / 3AML, MMF, MTX, AZA, CYC (7.8 g)1,5,7,10,11NephritisA/B0IVc/2.9 g
932 / 8AML, MTX, AZA, CyA, CYC (12.0 g)1,2,3,4,5,7,10,11Nephritis, destructive arthritis, neurological§A/B A/C B/C6IIIb/1.4 g
1035 / 9AML, AZA, MTX, CyA, MMF, IvIg, CYC (3.0 g)1,2,3,4,5,7,8,10,11Cutaneous, vasculitis¶B/D B/C2
1133 / 8AML, AZA, CyA, CYC (6.0 g)1,3,7,9,10,11NephritisA/B0Vb/ND
1255 / 1**AZA, CyA, MTX, AML, SSZ, leflunomid1,2,3,5,11Destructive arthritis, generalA/C B/C2
1350 / 16AML, plasmapheresis, CYC (6.0 g)2,5,6,11CutaneousA/D1
1449 / 24AZA, AML, CYC (4.7 g)1,5,7,9,10,11Neurological†† generalB/B B/B2
1543 / 22AML, AZA, CYC (14.7 g)1,3,4,5,6,7,8,9,10,11Nephritis, haematologicalA/D B/C4IVb/5.9 g
1629 / 1MMF, CYC (5.8 g)1,3,4,5,6,7,9,10,11Nephritis, general, haematological, serositisA/C A/C B/C A/B0IVb/2.4 g
  • *ACR (American College of Rheumatology) criteria for classification of SLE: 1, malar rash; 2, discoid rash; 3, photosensitivity; 4, oral ulcers; 5, arthritis; 6, serositis; 7, renal disorder; 8, neurological disorder; 9, haematological disorder; 10, immunological disorder, 11, antinuclear antibody.

  • †BILAG (British Isles Lupus Assessment Group) scores for main organ manifestations at baseline and after six months of follow up: category A to E, where A represent the highest scoring in that particular organ system; D = previous involvement; E = no previous involvement; B and C lie in between and can be assessed as moderate and mild involvement, respectively.

  • ‡Vasculitis = minor cutaneous and thromboembolism.

  • §Neurological = depression, headache, cognitive impairment.

  • ¶Vasculitis = minor cutaneous vasculitis and superficial phlebitis.

  • **This patient had earlier a diagnosis of rheumatoid arthritis and mixed connective tissue disease but one year prior to rituximab treatment was reclassified as SLE.

  • ††Neurological = severe depression with suicidal risk, cognitive impairment.

  • AML, antimalarials; AZA, azathioprine; CyA, ciclosporine A; CYC, cyclophosphamide; IvIg, intravenous immunoglobulins; MMF, mycophenolate mofetil; MTX, methotrexate; ND, not determined; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index9; SSZ, sulfasalazine.